The EASEE® innovation is seen as a real opportunity for epilepsy patients by leading neuroscientist. You can order selected publications here.
Evaluations to download
Papers to order
For ‘pharmacoresistant’ patients, the use of high-frequency stimuli and direct current application represent potential access points for modulating the specific brain region that is generating epileptic seizures. This is a novel approach to seizure control.
When medications are insufficiently helpful for the treatment of epilepsy, stimulation techniques open up new possibilities. Such interventions differ in their degree of invasiveness and the focal specificity of the stimulation.
Order the publications:
Request the folder for neurologists
If you are a physician or medical professional, you have the option here to request the folder about EASEE® for focal epilepsy. Since the Drug Advertising Law obligates us only to send advertising materials to qualified professionals, we ask that you provide your full professional title and address.
Order the paper here:
Good prospects for the future. You can read about our progress and milestones, about our expansions and our experts, about our engagement and exchanges, in brief: about everything that motivates us.
- Clinical Studies Demonstrate that Patients with Focal Epilepsies Benefit from the Technologically Innovative Therapy EASEE®
Heidelberg, 4/29/2022 – Prof. Andreas Schulze-Bonhage, MD, Head of the Epilepsy Center at the University Hospital Freiburg, who is responsible for the multi-center study on the efficacy of EASEE®, presented the impressive results of the globally unparalleled procedure for the treatment of patients with focal epilepsies in […]
- Minimally Invasive Epilepsy Treatment EASEE® Receives FDA Breakthrough Device Designation
Heidelberg, 2/21/2022 – Heidelberg-based Precisis GmbH has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its EASEE® brain stimulator. FDA’s breakthrough devices program classifies medical devices that have the potential to enable more effective treatment of life-threatening o […]
- Precisis concludes funding round of €20 million for its bioelectric brain stimulation system
Heidelberg, 10/21/2021 – Today, Precisis GmbH, based in Heidelberg, announced that it has successfully concluded a funding round of €20 million with Cochlear Limited. Precisis is a medical technology company that develops minimally invasive brain stimulation methods to relieve epilepsy patients from their symptoms.